Uncategorized
Ozurdex Approved as Treatment for Noninfectious Uveitis of the Posterior Segment
The US Food and Drug Administration (FDA) has
approved Ozurdex (dexamethasone intravitreal implant
0.7 mg; Allergan, Inc.) for the treatment of noninfectious
uveitis affecting the posterior segment, according to a
company news release.
Ozurdex is a biodegradable implant that delivers an
extended release of the cortico...